.Pharmacolibrary.Drugs.ATC.J.J01GB09 .Pharmacolibrary.Drugs.ATC.J.J01GB09| name: | Dibekacin | |
| ATC code: | J01GB09 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 100 | mg |
| volume of distribution: | 0.25 | L |
| clearance: | 80 | ml/min |
| other parameters in model implementation | ||
Dibekacin is an aminoglycoside antibiotic structurally related to kanamycin, primarily used to treat severe infections caused by Gram-negative bacteria, particularly Pseudomonas aeruginosa. Its usage has been limited or discontinued in many countries and is generally not considered a first-line therapy today due to the availability of other aminoglycosides and concerns about toxicity.
Estimated pharmacokinetic parameters for dibekacin in adult patients, based on analogy with other aminoglycosides (such as amikacin and kanamycin) due to lack of published specific data.
Lakota, EA, et al., & Rubino, CM (2019). Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution. Antimicrobial agents and chemotherapy 63(8) –. DOI:10.1128/AAC.00267-19 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31182524